Webinar on-demand: Available to view until midnight July 9, 2021 (registration is required)

Non-alcoholic steatohepatitis (NASH) is a major unmet health need and currently a significant, growing worldwide cause of chronic liver disease with an ever-increasing toll on cirrhotic morbidity, hepatocellular carcinoma and liver transplantation. Predisposing conditions such as adipose tissue insulin resistance, adipocytokine imbalance and systemic inflammation promote hepatic lipotoxicity, leading to inflammatory and fibrotic liver injury.
NASH is a multi-system disease with cardiovascular complications, worsening of metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers.
Both the management and treatment of NASH require a holistic approach. Peroxisome proliferator-activated receptors (PPARs) have been shown to have a role in several and complementary physiological processes including carbohydrate and lipid metabolism as well as inflammation and fibrogenesis, and represent a promising target for therapy. Ongoing clinical trials suggest that dual and especially pan-PPAR agonists might have a broader and more efficient therapeutic potential to affect the multisystem disease of NASH by targeting different interrelated mechanisms in its pathophysiology.
This Pan NASH interactive webinar will discuss these important scientific issues with a global and interdisciplinary perspective.

Educational Objectives

  • Review the latest epidemiological data about NAFLD and NASH, and how the burden of the disease extends beyond liver manifestations
  • Understand the pathogenesis and natural course of NAFL and NASH, and the rational for addressing NAFLD and NASH as part of a multisystem disease.
  • Discuss the relationship between NASH and the risk of developing cardiovascular diseases, aggravating insulino-resistance and other extra-hepatic diseases.
  • Evaluate the latest research options for the treatment of NASH and their potential implications for clinical practice.
  • Apply findings from clinical trials into clinical practice


Featured image
Prof. Sven Francque

Chairman of the Department of Gastroenterology and Hepatology, University Hospital Antwerp

Featured image
Prof. Manal F. Abdelmalek

Professor of Medicine, Division of Gastroenterology & Hepatology, Duke University

Featured image
Prof. Christopher Byrne

Professor Endocrinology & Metabolism, University Hospital Southampton

Featured image
Prof. Kenneth Cusi

Chief, Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville

Featured image
Prof. Arun Sanyal

Z Reno Vlahcevic Professor of Medicine, Virginia Commonwealth University School of Medicine

Featured image
Dr. Jordi Gracia-Sancho

Chief of the Liver Vascular Biology Research Group, IDIBAPS Research Institute – Hospital Clínic de Barcelona and Department of Biomedical Research – University of Bern

Webinar agenda

17:00 – 17:10
Welcome and Introduction to the webinar
S. Francque
17:10 – 17:20
NASH overview in 2021
A. Sanyal
17:20 – 17:30
NASH and CV system and risks
C. Byrne
17:30 – 17:40
NASH and hepatic vascularization
J. Gracia
17:40 – 17:50
NASH and insulin resistance (and CV consequences)
K. Cusi
17:50 – 18:00
Current progress and future promise: the therapeutic approaches
M. Abdelmalek
18:00 – 18:20
18:20 – 18:30
Conclusion and take-home messages
S. Francque
PanNASH™ initiative, a working group consisting of a committee of international independent experts that aims to increase the visibility and contribute to a better understanding of NASH (a multisystem disease), to share their expertise and to establish best practices for the treatment of the disease has been supported since three years by Inventiva S.A. a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS).
The committee, which is entirely funded by Inventiva, includes European, American and Asian medical experts in areas related to NASH such as hepatology, diabetes and cardiology, along with renowned scientific experts focused on promoting a better understanding of the physiopathological mechanisms involved in NASH (see the list of the founding members in PanNASH initiative web site – www.pannash.org). Their aim will therefore be to play an active role in developing and disseminating their NASH expertise among the scientific community, patients and other key stakeholders within the healthcare system.
In particular, the experts group intends to help develop and share new findings about NASH through scientific publications, conferences and training sessions. It will particularly focus on the development of the disease as a multi-system disease, the identification of patients at risk, clinical markers and associated health risks, as well as the development of new treatments. Specifically, the committee will help to increase knowledge of pathological mechanisms ranging from metabolic disorders to fibrosis and comorbidities, with a focus on the modulating role played by PPARs (peroxisome proliferator-activated receptors, α, δ, ɣ subtypes).